Pascal Leuraud

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.